Michael P. Cecil, M.D.

Health care reform is likely this year. How will that affect your pharma investments?

The man who might replace the king writes about his own business principles and strategies.

A cardiologist examines the Enhance trial results.

More bad news for Vytorin.

Fool contributor Dr. Michael Cecil is a cardiologist with extensive experience caring for patients as young as 111. He is also the author of Drugs for Less: The Complete Guide to Free and Discounted Drugs. Today, he hits the pages of Rule Your Retirement to talk about our most important asset: our health.

More and more, they're popping up overseas.

How young? One visitor to the Berkshire Hathaway meeting isn't old enough for a paper route.

New study results could affect stent sales -- at least in the short term.

Will Chantix help Pfizer cure its ailing stock price?

One of the bedrock principles of our economic system is that those buying more of a product receive a discount.

The very nature of the pharmaceutical business makes valuing such companies difficult.

In "surprising and disappointing" news, its promising new drug fails clinical trials.

The merger says a lot about companies that sell pharmaceuticals trying to deal with a rapidly changing paradigm.

One study could boost the stock of a company with a special machine for heart patients.

New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner and fewer sales of the stents.

Medicare law changes may drive the amount that hospitals can pay for pacemakers.

Celebrex is still shown to increase the risk of heart problems, but that might not be bad news for Pfizer shareholders.

On rare occasion I enjoy eating delicious, tasty treats from Dunkin' Donuts. Known as Munchkins, these ball-shaped delights look as if they were popped right out of the center of a doughnut. And while these fried holes are sugary sweet, the "doughnut hole" that millions of Medicare recipients are uncovering in their Medicare Part D plans is a financial hardship, not a treat.

Wal-mart's $4 generic-drug program could be the start of big changes in the $250 billion prescription-drug market.